Mexico - Latin America Immunosuppressant Drugs Market
The immunosuppressant drugs market in Mexico - Latin America is expected to reach a projected revenue of US$ 1,965.9 million by 2027. A compound annual growth rate of 8.3% is expected of Mexico - Latin America immunosuppressant drugs market from 2021 to 2027.
In terms of revenue, Mexico accounted for 1.2% of the global immunosuppressant drugs market in 2020.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
In Latin America, Brazil immunosuppressant drugs market is projected to lead the regional market in terms of revenue in 2027.
Mexico is the fastest growing regional market in Latin America and is projected to reach USD 1,965.9 million by 2027.
According to WHO, gum disease and untreated cavities are very rampant in Mexico and 90% of the Mexican population has untreated cavities, and Mexico’s health ministry states that the country’s six million people over the age of 65 have an average of 18 missing or damaged teeth out of 32. Age related dental disorders is surging in the country.
Dental care is a big business in Mexico with Los Algodones being a self-proclaimed capital of Mexican dentistry having over 600 dentist in vicinity Dental tourism destinations like Los Algodones attracts Canadians, because that country’s national health care system doesn’t include dental coverage.
Patients from America and Canada save up to 60 to 40 % of their dental cost when treated in Mexico. The cost of medical care is less expensive in Mexico primarily because the cost of running the business or a hospital or a clinic or even a doctor’s office is quite low compared to the U.S.
Mexico - Latin America Immunosuppressant Drugs Market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Immunosuppressant Drugs Market will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 72.73% in 2020.
Horizon Databook has segmented the Mexico - Latin America immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
According to WHO, gum disease and untreated cavities are very rampant in Mexico and 90% of the Mexican population has untreated cavities, and Mexico’s health ministry states that the country’s six million people over the age of 65 have an average of 18 missing or damaged teeth out of 32. Age related dental disorders is surging in the country.
Dental care is a big business in Mexico with Los Algodones being a self-proclaimed capital of Mexican dentistry having over 600 dentist in vicinity Dental tourism destinations like Los Algodones attracts Canadians, because that country’s national health care system doesn’t include dental coverage.
Patients from America and Canada save up to 60 to 40 % of their dental cost when treated in Mexico. The cost of medical care is less expensive in Mexico primarily because the cost of running the business or a hospital or a clinic or even a doctor’s office is quite low compared to the U.S.
Mexico - Latin America Immunosuppressant Drugs Market Drug Class Outlook (Revenue, USD Million , 2016-2027)
Calcineurin Inhibitors
mTOR Inhibitors
Antiproliferative Agents
Monoclonal Antibodies
Others
Mexico - Latin America Immunosuppressant Drugs Market Application Outlook (Revenue, USD Million , 2016-2027)
Autoimmune Diseases
Organ Transplants
Other Applications
Mexico - Latin America Immunosuppressant Drugs Market Route of Administration Outlook (Revenue, USD Million , 2016-2027)
Oral
Injectables
Mexico - Latin America Immunosuppressant Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2016-2027)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Reasons to subscribe to Immunosuppressant Drugs Market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Immunosuppressant Drugs Market databook
Our clientele includes a mix of Immunosuppressant Drugs Market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico - Latin America Immunosuppressant Drugs Market, including forecasts for subscribers. This country databook contains high-level insights into Mexico - Latin America Immunosuppressant Drugs Market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Mexico - Latin America Immunosuppressant Drugs Market, 2016-2027 (US$M)